Last $3.15 USD
Change Today -0.29 / -8.43%
Volume 170.9K
BCLI On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ CM
As of 8:10 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

brainstorm cell therapeutics (BCLI) Snapshot

Open
$3.49
Previous Close
$3.44
Day High
$3.49
Day Low
$3.07
52 Week High
07/8/14 - $5.70
52 Week Low
12/30/13 - $2.03
Market Cap
48.1M
Average Volume 10 Days
66.2K
EPS TTM
--
Shares Outstanding
15.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BRAINSTORM CELL THERAPEUTICS (BCLI)

brainstorm cell therapeutics (BCLI) Related Bloomberg News

View More Bloomberg News

brainstorm cell therapeutics (BCLI) Related Businessweek News

No Related Businessweek News Found

brainstorm cell therapeutics (BCLI) Details

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis. It holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. The company’s NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor and brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. It is developing NurOwn, an autologous adult stem cell product for the treatment of ALS. Brainstorm Cell Therapeutics Inc. also has agreements with Hadasit Medical Research Services and Development Ltd. to conduct its ALS clinical trials at the Hadassah Medical Center. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics was founded in 2000 and is based in New York, New York.

15 Employees
Last Reported Date: 11/13/14
Founded in 2000

brainstorm cell therapeutics (BCLI) Top Compensated Officers

President
Total Annual Compensation: --
Chief Financial Officer and Principal Account...
Total Annual Compensation: $106.0K
Compensation as of Fiscal Year 2013.

brainstorm cell therapeutics (BCLI) Key Developments

Brainstorm Cell Therapeutics Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended Sept. 30, 2014

Brainstorm Cell Therapeutics Inc. announced unaudited earnings results for the third quarter and nine months ended Sept. 30, 2014. For the quarter, the company reported operating loss of $2,419,000 against $1,081,000 a year ago. Net loss in the third quarter 2014 was $2.4 million, or $0.16 per common share, as compared to a net loss of $1.1 million, or $0.10 per common share, in the third quarter of 2013. For the nine months, the company reported operating loss of $6,514,000 against $3,663,000 a year ago. For the first nine months of 2014, net loss was $6.5 million, or $0.50 per common share, compared to a net loss of $3.7 million, or $0.36 per common share, for the same period in 2013.

Brainstorm Cell Therapeutics Inc. to Report Q3, 2014 Results on Nov 13, 2014

Brainstorm Cell Therapeutics Inc. announced that they will report Q3, 2014 results at 9:00 AM, Eastern Standard Time on Nov 13, 2014

Brainstorm Cell Therapeutics Inc., Q3 2014 Earnings Call, Nov 13, 2014

Brainstorm Cell Therapeutics Inc., Q3 2014 Earnings Call, Nov 13, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BCLI:US $3.15 USD -0.29

BCLI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BCLI.
View Industry Companies
 

Industry Analysis

BCLI

Industry Average

Valuation BCLI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 5.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BRAINSTORM CELL THERAPEUTICS, please visit www.brainstorm-cell.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.